Product Description

Product Name: Dolutegravir(S/GSK1349572)

CAS No.1051375-16-6

Information: HIV integrase inhibitor, novel and potent

Description: Dolutegravir (GSK1349572) is an inhibitor of two-metal-binding HIV integrase with an IC50 value of 2.7 nM.

Other Names: S/GSK1349572, GSK-1349572

Chemical Name: (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide

Canonical SMILES: CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O

MF: C20H19N3O5F2

MW: 419.37876

Assay: 99% min

Type: Anti-HIV Agents

Grade Standard: Medicine Grade

Brand Name: Huavet

Solubility Soluble in DMSO > 10 mM 

Storage: Store at -20°C 

General tips: For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. 

Shipping Condition: Evaluation sample solution: ship with blue ice. All other available size: ship with RT , or blue ice upon request

Background: Dolutegravir(S/GSK1349572), also known as dolutegravir, is a novel and potent inhibitor of human immunodeficiency virus (HIV) integrase (IN) blocking the strand transfer of integration of the viral genome into the host cell’s DNA. It occupies the physical space in the IN active site of the intasome, contacts with the β4-α2 loop of the catalytic core domain, and enters into the pocket vacated by the displaced viral DNA through its extended linker region connecting the metal chelating core the halobenzyl group.  S/GSK1349572 exhibits potent anti-HIV activity in peripheral blood mononuclear cells (IC50 = 0.51 nM) in vitro and retains activity against raltegravir- and elvitegravir- resistant HIV.

Reference

Sherene Min, Ivy Song, Julie Borland, Shuguang Chen, Yu Lou, Tamio Fujiwara, and Stephen C. Piscitelli. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2010; 54(1): 254-258

Masanori Kobayashi, Tomokazu Yoshinaga, Takahiro Seki, Chiaki Wakasa-Morimoto, Kevin W. Brown, Robert Ferris, Scott A. Foster, Richard J. Hazen, Shigeru Miki, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A. Johns, Mark R. Underwood, Edward P. Garvey, Akihiko Sato, and Tamio Fujiwara. In vitro antiretroviral prooerties of S/GSK1349572, a next-generation HIV integrase inhibitor. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2011; 55(2): 813-821

Stephen Harem Steven J. Smith, Mathieu Metifiot, Albert Jaxa-Chamiec, Yves Pommier, Stephen H. Hughes, and Peter Cherepanov. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).  Mol Pharmacol 2011; 80(4): 565-572

Usage: Pharmaceutical Intermediates

Inventory status: in stock

Shelf life: 2 years

Sample: Available

COA (Certificate Of Analysis): Available

MSDS (Material Safety Data Sheet): Available

HPLC Spectrum: Available

ISO: Approved

GC: Available

NMR (Nuclear Magnetic Resonance): Available

Packaging Details: 1g,5g,10g,50g,100g/bottle, 1kg/tin for trial order,25kg/drum for commercial quantity. Specific packing required by customer

Delivery Detail: Prompt shipment